Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 61 - 70 of 120

Selected Filters:
18 April 2023

Report: Formative research on CAB for PrEP in Eswatini

The goal of this study was to assess access needs, product acceptability, values, and preferences for the new PrEP method. This activity was a collaboration between EpiC and MOSAIC, and included adolescent girls and young women, men who have sex with men, people who inject drugs, female sex workers, pregnant and breastfeeding populations, and transgender…

Research

External Link
14 April 2023

Coordinating Implementation Science for CAB for PrEP: Bridging from the HPTN 083 and 084 Open Label Extensions to Implementation

This document summarises key takeaways from the BioPIC Think Tank on early insights from the HIV Prevention Trials Network (HPTN) 083 and 084 studies’ Open Label Extensions, looking at effectiveness of cabotegravir for PrEP as HIV prevention.

Research

Document
12 April 2023

Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction Report

This report was from the BioPIC Think Tank, Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction. As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and FP…

Demand Creation/Marketing

Document
12 April 2023

Safety and Efficacy of Long-Acting Injectable Cabotegravir as Preexposure Prophylaxis To Prevent HIV Acquisition

This journal article from AIDS reviewed existing evidence to determine the efficacy and safety of CAB for PrEP in order to inform global guidelines.

Monitoring & Evaluation

External Link
10 April 2023

Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction Slides

These slides were featured at the BioPIC Think Tank, Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction. As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and…

Demand Creation/Marketing

Presentation
6 April 2023

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

This journal article from Antimicrobial Agents and Chemo Therapy shares an extended report on HIV infections that occurred up to 1 year after study unblinding (18 in the CAB arm and 34 in the TDF-FTC arm).

Monitoring & Evaluation

External Link
17 March 2023

Guidance: Standard Operating Procedures for Addressing Partner Relationships and Gender-Based Violence in Pre-Exposure Prophylaxis (PrEP) Services

Standard Operating Procedure Guidance Evidence has shown that intimate partner violence (IPV) may act as a barrier to accessing HIV services, including PrEP services. IPV is associated with lower PrEP uptake and adherence and increased PrEP interruption among cisgender women. Although cisgender women have made up the majority of participants in research on PrEP and…

Normative Guidance/Policies, Service Delivery

Document
9 March 2023

Making PrEP accessible: Updates on long-acting injectable options

Recording The objective of this webinar, presented by the International AIDS Society is to provide the latest updates on long-acting injectable PrEP, including science and research emerging from recent conferences. Participants will also hear the civil society perspective on the evolving PrEP landscape, as well as on-the-ground approaches to increase access to long-acting PrEP. Moderator:…

Community/Advocacy, Research

Event
17 February 2023

New PrEP Product Implementation Roadmap for PrEP vaginal ring and CAB for PrEP in Uganda

This presentation outlines the timelines for implementation of the dapivirine vaginal ring and cabotegravir (CAB) for PrEP in Uganda.

Research, Service Delivery

Document
17 February 2023

Daily Oral PrEP, Event-Driven PrEP, PrEP Ring, and CAB PrEP Template Guidelines (French)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based daily and event-driven oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and…

Normative Guidance/Policies

Document